Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Evolocumab (Repatha – Amgen), a subcutaneously injected PCSK9 inhibitor, has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C) (Table 1). It was also approved as an adjunct to diet and other LDL-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C. Evolocumab is the second PCSK9 inhibitor to be approved in the US; alirocumab (Praluent) was approved earlier (Table 2).1
Evolocumab (Repatha)—A Second PCSK9 Inhibitor to Lower LDL-Cholesterol. JAMA. 2015;314(21):2298–2299. doi:10.1001/jama.2015.14772
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: